Special Issue "Safety and Benefits of Modern Hormonal Contraceptives"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 15 November 2021.

Special Issue Editors

Dr. Giovanni Grandi
E-Mail Website
Guest Editor
Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Via del Pozzo 71, 41124 Modena, Italy
Interests: hormonal contraception; estrogen; progestin; BRCA; gynecological cancer
Dr. Maria Chiara del Savio
E-Mail Website
Guest Editor
Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Via del Pozzo 71, 41124 Modena, Italy
Interests: hormonal contraception; SARC; LARC; intrauterine device; levonoregestrel-releasing intrauterine device; progestin

Special Issue Information

Dear colleagues,

The reduction of health-related risks is an important hallmark in the field of women’s health care. This is of primary interest for contraceptive drugs, which are usually prescribed to healthy women with the sole purpose of avoiding unintended pregnancy. Therefore, the ideal contraceptive would be one that eliminates, or greatly reduces, the risk of harm and adverse events while maintaining a similar efficacy, with many additional possible health benefits for the user. With the latest evolution of contraception technology, many modern hormonal contraceptives—both short and long-acting—meet these prerequisites. The aim of this Special Issue is to highlight the latest discoveries in this broad topic, and to offer clinicians additional safety data for the use of these drugs of daily use.

Dr. Giovanni Grandi
Dr. Maria Chiara del Savio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hormonal contraceptives
  • pills
  • vaginal ring
  • patch
  • levonorgestrel intrauterine system
  • combined hormonal contraceptives
  • estradiol
  • ethinylestradiol
  • progestin
  • venous thrombo-embolism
  • benefits
  • bone
  • dysmenorrhea
  • metabolism
  • lipids
  • glucose
  • diabetes
  • cardiovascular

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Safety and Benefits of Contraceptives Implants: A Systematic Review
Pharmaceuticals 2021, 14(6), 548; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060548 - 08 Jun 2021
Viewed by 750
Abstract
Progestin-only contraceptive implants provide long-acting, highly effective reversible contraception. We searched the medical publications in PubMed, CENTRAL, and EMBASE for relevant articles on hormonal implants published in English between 1990 and 2021. Levonorgestrel (LNG) 6-capsule subdermal implants represented the first effective system approved [...] Read more.
Progestin-only contraceptive implants provide long-acting, highly effective reversible contraception. We searched the medical publications in PubMed, CENTRAL, and EMBASE for relevant articles on hormonal implants published in English between 1990 and 2021. Levonorgestrel (LNG) 6-capsule subdermal implants represented the first effective system approved for reversible contraception. The etonogestrel (ENG) single rod dispositive has been widely employed in clinical practice, since it is a highly effective and safe contraceptive method. Abnormal menstrual bleeding is a common ENG side effect, representing the main reason for its premature discontinuation. Emerging evidence demonstrated that it is possible to extend the use of the ENG implant beyond the three-year period for which it is approved. The ENG implant could be an effective and discrete alternative to the IUD in young girls, such as post-partum/post-abortion. Implants should be inserted by trained skilled clinicians who previously provide adequate counselling about their contraceptive effect, benefits, and any possible adverse events. More studies are needed to validate the extended use of the ENG implant for up to 5 years. Full article
(This article belongs to the Special Issue Safety and Benefits of Modern Hormonal Contraceptives)
Show Figures

Figure 1

Back to TopTop